Karen O’Hanlon Cohrt, Author at Labiotech.eu

About

Karen O’Hanlon Cohrt is a Science Writer and Editor with a PhD in biotechnology from Maynooth University, Ireland.

Articles by Karen O’Hanlon Cohrt

In Depth 4 Jan 2021

What Does the Next Decade Have in Store for European Biotech?

Just like that, another decade has gone by. It’s time to look at what the future will bring to the European biotech industry. European biotech has seen some huge breakthroughs…

January 4, 2021 - 9 minutesmins - By Karen O’Hanlon Cohrt

In Depth 30 Dec 2020

A Look Back at the Past Decade of European Biotech

As we prepare to enter a new decade, we look back on the major milestones and blunders within European biotech over the last 10 years. Over the last decade, we…

December 30, 2020 - 15 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 7 May 2020

Lyme Disease Vaccine Gets Pfizer’s Backing in €284M Deal

The French biotech Valneva will collaborate with Pfizer to develop and commercialize Valneva’s phase II-stage Lyme disease vaccine candidate. The deal they signed is expected to help compensate for the…

May 7, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 27 Apr 2020

Series A Round Boosts Swedish Synthetic Biology Player by €6.4M

The Swedish synthetic biology company EnginZyme has raised a Series A funding round to the tune of €6.4M to develop its cell-free synbio technology for the sustainable production of plastic,…

April 27, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 21 Apr 2020

Idorsia’s Drug Improves Sleep in First Phase III Trial for Insomnia

The Swiss pharmaceutical company Idorsia has announced that its drug candidate daridorexant significantly improved sleep onset, sleep quality, and daytime functioning of insomnia patients in a pivotal phase III trial. …

April 21, 2020 - 3 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 31 Mar 2020

Ipsen Resumes Phase III Testing for Rare Disease Drug and Abandons Pediatric Trial

The French pharmaceutical company Ipsen has restarted the dosing of its treatment for a rare bone disease in a phase III trial after obtaining questionable interim results. At the same…

March 31, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

Best in Biotech 20 Jan 2020

How Much Salary Can You Expect in a Biotech Job?

If you’re thinking of taking a job in biotech, you’re probably wondering how much you’ll be paid. Here’s what you can expect depending on how high in the ladder your…

January 20, 2020 - 7 minutesmins - By Karen O’Hanlon Cohrt

In Depth 25 Mar 2019

Where Does Brexit Leave European Biotech?

In the next couple of months, the UK will officially exit the EU, in a move that is popularly known as Brexit. With this date fast approaching, companies, organizations and…

March 25, 2019 - 9 minutesmins - By Karen O’Hanlon Cohrt

Best in Biotech 30 Apr 2018

The 5 Best-Selling European Drugs of 2017

Biologicals have completely changed the way we treat diseases, and their growth has exploded in the last two decades. Not surprisingly, they took a whopping 7 out of 15 spots…

April 30, 2018 - 7 minutesmins - By Karen O’Hanlon Cohrt

Best in Biotech 20 Feb 2018

Money, Money, Money! Europe’s Best-Funded Biotechs in 2018

Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where many of us re-examine our finances and budget for the year ahead. With money on…

February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering